a reliable partner at the heart of Europe
since its foundation in 2008, Firalis Group has been awarded for and contributed in about a
hundred high-ranked research projects in biomarkers, playing a leading role towards the setting of
industry gold standards for the discovery, development and qualification of novel clinical biomarkers
Why Firalis ?
Firalis provides a comprehensive range of biomarker services from research to clinical qualification. Stratification at scientific and technical levels support biomarker discovery, validation, evaluation and qualification. Using our strong expertise and cutting-edge laboratory equipment, we develop and deliver customized solutions for biomarker assays according to your project needs.
Who we are?
Firalis is involved in several large scale projects for qualification of biomarkers in various clinical applications and led the efforts to improve industry standards, as the initiator of the SAFE-T consortium, largest ever biomarker research project co-funded by EU-IMI and Pharma.Today, Firalis validates and develops biomarker panels, following strictly the EMA and FDA directions.
What we do?
Firalis develops bioanalytical tools in compliance with the highest quality standards. Our kits are designed and processed in a GMP compliant production facility "ISO 13485", being the international norm for medical device manufacture and our services are executed in laboratories certified "ISO 17025", which is the most important quality standard
for calibration and testing.